Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Sernova Biotherapeutics Inc. (SEOVF : OTC)

• Company Description    Sernova Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cells to create a bio-hybrid organ. Sernova Biotherapeutics, formerly known as Sernova Corp., is based in LONDON, Ontario. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $0.11 Daily Weekly Monthly 20 Day Moving Average: 11,744 shares Shares Outstanding: 328.69 (millions) Market Capitalization: $35.07 (millions) Beta: 1.06 52 Week High: $0.18 52 Week Low: $0.10 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -16.58% -18.76% 12 Week -26.77% -29.80% Year To Date -28.87% -37.82%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 700 COLLIP CIRCLE SUITE 114 - LONDON,A6 N6G 4X8 CAN ph: 519-858-5184 fax: 519-858-5099 david.burke@sernova.com http://www.sernova.com

• General Corporate Information    Officers Jonathan Rigby - Chairman; President and Chief Executive Officer James Parsons - Chief Financial Officer Bernd Muehlenweg - Director David Paterson - Director Steven Sangha - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 81752F106 SIC: 2834 Fiscal Year Fiscal Year End: October Last Reported Quarter: 07/01/25 Next Expected EPS Date: 12/22/25 Share - Related Items Shares Outstanding: 328.69 Most Recent Split Date: (:1) Beta: 1.06 Market Capitalization: $35.07 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 12/22/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 10/31/25 - - 07/31/25 - - 04/30/25 - - ROA 10/31/25 - - 07/31/25 - -475.30 04/30/25 - -396.49 Current Ratio 10/31/25 - - 07/31/25 - 0.02 04/30/25 - 0.12 Quick Ratio 10/31/25 - - 07/31/25 - 0.02 04/30/25 - 0.12 Operating Margin 10/31/25 - - 07/31/25 - - 04/30/25 - - Net Margin 10/31/25 - - 07/31/25 - - 04/30/25 - - Pre-Tax Margin 10/31/25 - - 07/31/25 - - 04/30/25 - - Book Value 10/31/25 - - 07/31/25 - -0.05 04/30/25 - -0.04 Inventory Turnover 10/31/25 - - 07/31/25 - - 04/30/25 - - Debt-to-Equity 10/31/25 - - 07/31/25 - - 04/30/25 - - Debt-to-Capital 10/31/25 - - 07/31/25 - - 04/30/25 - -

Powered by Zacks Investment Research ©